In this article, we delve into a comprehensive analysis of Orchid Pharma share price targets for the years 2024, 2025, 2026, 2027, 2030, 2040, and 2050. Our examination spans various perspectives, including financial metrics, fundamental analysis, technical analysis, and more.
Table of Contents
About
Orchid Pharma is a pharmaceutical company specializing in the research, development, and production of active pharmaceutical ingredients (APIs) and finished dosage forms. With a diverse portfolio, it operates across various therapeutic segments including anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular (CVS), nutraceuticals, and other oral and sterile products.
In addition to manufacturing APIs and finished dosage forms, Orchid Pharma is actively involved in the research of new drugs, offering comprehensive pharmaceutical solutions to its customers.
Founded | 1st July 1992 |
NSE Symbol | ORCHPHARMA |
IPO | in 1993 |
Chairman & Non Executive Director | Mr. Ram Gopal Agarwal |
Sector | Pharma |
Headquarters | Chengalpattu, Tamil Nadu |
Official Website | orchidpharma.com |
Also Read : Azad Engineering share price target 2024, 2025, 2026, 2027 to 2030
Financial Details
As of January 30, 2024, Orchid Pharma’s market capitalization stands at ₹4,404 crores, reflecting the total market value of its outstanding shares.
The stock’s price-to-earnings (P/E) ratio is relatively high at 69.4, indicating investors are willing to pay more for each unit of earnings.
The return on capital employed (ROCE) is modest at 4.97%, suggesting the company generates less profit per unit of capital invested compared to industry standards.
Similarly, the return on equity (ROE) is also relatively low at 0.95%, indicating the company’s efficiency in utilizing shareholders’ equity to generate profit is below par.
On a positive note, Orchid Pharma maintains a low debt-to-equity ratio of 0.13, indicating a conservative capital structure with a relatively low level of debt compared to equity. The company’s total debt stands at ₹147 crores, suggesting a manageable level of financial leverage.
Foreign institutional investors (FIIs) hold a stake of 4.14% in the company, while domestic institutional investors (DIIs) have a higher stake of 14.5%, indicating a level of confidence from institutional investors.
Despite modest profitability ratios, Orchid Pharma has demonstrated robust sales growth of 18.2%, indicating strong demand for its pharmaceutical products and potential for future revenue expansion.
Market Cap | ₹ 4,404 Cr | Stock P/E | 69.4 |
ROCE | 4.97 % | ROE | 0.95 % |
Debt to equity | 0.13 | Debt | ₹147Cr. |
FII Holding | 4.14 % | DII Holding | 14.5 % |
EPS | ₹22.1 | Sales growth | 18.2% |
Also Read : Qualitek Labs Ltd share price target 2024, 2025, 2026 to 2030
Financial Statement
In the trailing twelve months (TTM) period, Orchid Pharma witnessed a notable increase in net sales, reaching ₹751 crores compared to ₹666 crores in 2023 and ₹560 crores in 2022, indicating a positive trend in revenue growth.
However, corresponding expenses also rose, reaching ₹653 crores in the TTM period, up from ₹581 crores in 2023 and ₹505 crores in 2022, potentially impacting profit margins.
Despite the increase in expenses, the company managed to achieve a significant profit after tax of ₹96 crores in the TTM period, increased from profit after tax of 56 crores in 2023 and a loss of -2 core in 2022 and a larger loss of ₹117 crores in 2021. This positive performance in profitability suggests effective cost management strategies and potential opportunities for further growth and expansion.
Particulars | TTM* | 2023 | 2022 | 2021 |
---|---|---|---|---|
Net Sales | 751 | 666 | 560 | 450 |
Expenses | 653 | 581 | 505 | 421 |
Profit After Tax | 96 | 46 | -2 | -117 |
TTM*= Trailing Twelve Months
Also Read : Shri Balaji Valve Components Ltd share price target 2024, 2025, 2026 to 2030
Table of Orchid Pharma Share Price Target
Year | Min Target | Max Target |
---|---|---|
Orchid Pharma Share Price Target 2024 | ₹935 | ₹972 |
Orchid Pharma Share Price Target 2025 | ₹1,011 | ₹1,051 |
Orchid Pharma Share Price Target 2026 | ₹1,093 | ₹1,137 |
Orchid Pharma Share Price Target 2027 | ₹1,182 | ₹1,229 |
Orchid Pharma Share Price Target 2028 | ₹1,278 | ₹1,329 |
Orchid Pharma Share Price Target 2029 | ₹1,382 | ₹1,437 |
Orchid Pharma Share Price Target 2030 | ₹1,494 | ₹1,554 |
Also Read : Maxposure Limited share price target 2024, 2025, 2026, 2027 to 2030
Disclaimer
Investing in stock market is risky and subject to the market condition. This article provides an examination of the company for educational purposes only. We are not SEBI( Stock exchange board of India) registered advisors, and this is not an investment advice. We do not provide tips or calls. Before making any investment decisions, please conduct your own research or consult a qualified financial advisor.
You Might Like
- Kid Turns Into Crorepati in Just 4 Months. You Won’t Believe How He Pulled It Off!
- Koura Fine Diamond Jewelry share price target 2024, 2025, 2026, 2027 to 2030
- Sona Machinery Limited share price target 2024, 2025, 2026, 2027 to 2030
- R K Swamy limited share price target 2024, 2025, 2026 to 2030
- Platinum Industries Limited share price target 2024, 2025, 2026 to 2030
- Paisalo Digital Limited Share price target 2024, 2025, 2026, 2027 to 2030